Literature DB >> 7492077

Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones.

T Takenouchi1, C Ishii, M Sugawara, Y Tokue, S Ohya.   

Abstract

Point mutations in the gyrA genes of 451 clinical strains of Staphylococcus aureus isolated in Japan were detected by a combination of nonradioisotopic single-strand conformation polymorphism analysis and restriction fragment length polymorphism analysis and by direct sequencing. Six types of gyrA mutations were observed in 149 of the 451 strains (33%), and ofloxacin MICs were greater than 6.25 micrograms/ml for 147 of the 149 strains (98.7%). These mutations were localized between codons 84 and 88, and they were associated with fluoroquinolone resistance. Two types of silent mutations were also found. Among these eight types of mutations, three types are novel, i.e., the serine at position 84 (Ser-84)-->Val (TCA-->GTA), Ser-84-->Leu (TCA-->TTA) plus Ile-86 (ATT-->ATC, silent), and Phe-110 (TTT-->TTC, silent). Among GyrA mutants, strains with a Ser-84-->Leu alteration and strains with a Glu-88-->Lys alteration were dominant. In contrast, few strains had Ser-84-->Ala and Glu-88-->Gly alterations. All fluoroquinolones tested showed greater than a fourfold decrease in their activities in terms of their MICs that inhibited 50% of strains tested for each GyrA mutant, in comparison with their MICs that inhibited 50% of strains tested for susceptible strains. Most of the currently available fluoroquinolones, such as norfloxacin, enoxacin, ofloxacin, ciprofloxacin, tosufloxacin, lomefloxacin, sparfloxacin, and fleroxacin, were ineffective against each mutant. Mutants containing a Ser-84-->Leu or Val alteration showed high-level resistance to fluoroquinolones, and one containing a Ser-84-->Ala alteration showed relatively low-level resistance. Double mutations were associated with a higher level of resistance than single mutations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492077      PMCID: PMC162754          DOI: 10.1128/AAC.39.7.1414

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee.

Authors:  C E Fasching; F C Tenover; T G Slama; L M Fisher; S Sreedharan; M Oram; K Willard; L M Sinn; D N Gerding; L R Peterson
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

Review 2.  Fluoroquinolone antimicrobial agents.

Authors:  D C Hooper; J S Wolfson
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

Review 3.  Biochemical characteristics and physiological significance of major DNA topoisomerases.

Authors:  J A Sutcliffe; T D Gootz; J F Barrett
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

4.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

Authors:  S Sreedharan; M Oram; B Jensen; L R Peterson; L M Fisher
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

5.  Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones.

Authors:  H Yoshida; M Bogaki; S Nakamura; K Ubukata; M Konno
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

Review 6.  Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.

Authors:  P Ball
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

Review 7.  DNA gyrase: structure and function.

Authors:  R J Reece; A Maxwell
Journal:  Crit Rev Biochem Mol Biol       Date:  1991       Impact factor: 8.250

8.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

9.  Dissociated resistance among fluoroquinolones.

Authors:  K S Thomson; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins.

Authors:  E E Margerrison; R Hopewell; L M Fisher
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

View more
  19 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.

Authors:  N A el Amin; S Jalal; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.

Authors:  T Wang; M Tanaka; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

5.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 6.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

7.  Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

Authors:  T Takenouchi; F Tabata; Y Iwata; H Hanzawa; M Sugawara; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  Sequence of quinolone resistance-determining region of gyrA gene for clinical isolates and for an in vitro-selected quinolone-resistant strain of Coxiella burnetii.

Authors:  D Musso; M Drancourt; S Osscini; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.

Authors:  J E Fitzgibbon; J F John; J L Delucia; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.

Authors:  H Fukuda; S Hori; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.